Psychoneuroimmunology and cancer: Incidence, progression, and quality of life

Psychological Aspects of Cancer: A Guide to Emotional and Psychological Consequences of Cancer, Their Causes and Their Management

Volumn , Issue , 2013, Pages 1-11

  Fagundes, Christopher P ^a   Lindgren, Monica E ^a   Kiecolt Glaser, Janice K ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84948171351     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4614-4866-2_1     Document Type: Chapter

References (99)

1. Mukherjee S. The emperor of all maladies: A biography of cancer. New York: Scribner; 2010.
2. Glaser R, Kiecolt-Glaser JK. Stress-induced immune dysfunction: implications for health. Nat Rev Immunol. 2005; 5:243-51.
3. Chida Y, Hamer M, Wardle J, Steptoe A. Do stressrelated psychosocial factors contribute to cancer incidence and survival? Nat Clin Pract Oncol. 2008; 5:466-75.
4. Lillberg K, Verkasalo PK, Kaprio J, Teppo L, Helenius H, Koskenvuo M. Stressful life events and risk of breast cancer in 10,808 women: A cohort study. Am J Epidemiol. 2003; 157:415.
5. Penninx BWJH, Guralnik JM, Havlik RJ, et al. Chronically depressed mood and cancer risk in older persons. J Natl Cancer Inst. 1998; 90:1888.
6. Ross K. Mapping pathways from stress to cancer progression. J Natl Cancer Inst. 2008; 100:914.
7. Lutgendorf SK, Sood AK, Antoni MH. Host factors and cancer progression: biobehavioral signaling pathways and interventions. J Clin Oncol. 2010; 28:4094.
8. Palesh O, Butler LD, Koopman C, Giese-Davis J, Carlson R, Spiegel D. Stress history and breast cancer recurrence. J Psychosom Res. 2007; 63:233-9.
9. Watson M, Haviland J, Greer S, Davidson J, Bliss J. Influence of psychological response on survival in breast cancer: A population-based cohort study. Lancet. 1999; 354:1331-6.
10. Steel JL, Geller DA, Gamblin TC, Olek MC, Carr BI. Depression, immunity, and survival in patients with hepatobiliary carcinoma. J Clin Oncol. 2007; 25:2397.
11. Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients. Cancer. 2009; 115:5349-61.
12. Laconi E, Tomasi C, Curreli F, et al. Early exposure to restraint stress enhances chemical carcinogenesis in rat liver. Cancer Lett. 2000; 161:215-20.
13. Visintainer MA. Tumor rejection in rats after inescapable or escapable shock. Science. 1982; 216:437.
14. Fidler IJ. The pathogenesis of cancer metastasis: The 'seed and soil' hypothesis revisited. Nat Rev Cancer. 2003; 3:453-8.
15. Padgett DA, Glaser R. How stress Influences the immune response. Trends Immunol. 2003; 24:444-8.
16. Costanzo ES, Sood AK, Lutgendorf SK. Biobehavioral Influences on cancer progression. Immunol Allergy Clin North Am. 2011; 31:109-32.
17. Saharinen P, Eklund L, Pulkki K, Bono P, Alitalo K. VEGF and angiopoietin signaling in tumor angiogenesis and metastasis. Trends Mol Med. 2011; 17(7):347-62.
18. Yang EV, Kim SJ, Donovan EL, et al. Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun. 2009; 23:267-75.
19. Lutgendorf SK, Cole S, Costanzo E, et al. Stressrelated mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res. 2003; 9:4514-21.
20. Yang EV, Sood AK, Chen M, et al. Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res. 2006; 66:10357-64.
21. Lutgendorf SK, Johnsen EL, Cooper B, et al. Vascular endothelial growth factor and social support in patients with ovarian carcinoma. Cancer. 2002; 95:808-15.
22. Lutgendorf SK, Lamkin DM, Jennings NB, et al. Biobehavioral Influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res. 2008; 14:6839-46.
23. Sharma A, Greenman J, Sharp DM, Walker LG, Monson JR. Vascular endothelial growth factor and psychosocial factors in colorectal cancer. Psychooncology. 2008; 17:66-73.
24. Nausheen B, Carr NJ, Peveler RC, et al. Relationship between loneliness and proangiogenic cytokines in newly diagnosed tumors of colon and rectum. Psychosom Med. 2010; 72:912-6.
25. Shih JY, Yuan A, Chen JJW, Yang PC. Tumorassociated macrophage: its role in cancer invasion and metastasis. J Cancer Molecules. 2006; 2:101-6.
26. Sood AK, Bhatty R, Kamat AA, et al. Stress hormonemediated invasion of ovarian cancer cells. Clin Cancer Res. 2006; 12:369-75.
27. Nilsson MB, Armaiz-Pena G, Takahashi R, et al. Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Srcdependent mechanism. J Biol Chem. 2007; 282: 29919-26.
28. Costanzo ES, Lutgendorf SK, Sood AK, Anderson B, Sorosky J, Lubaroff DM. Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer. 2005; 104:305-13.
29. Sica A, Allavena P, Mantovani A. Cancer related Inflammation: The macrophage connection. Cancer Lett. 2008; 267:204-15.
30. Tsutsui S, Yasuda K, Suzuki K, Tahara K, Higashi H, Era S. Macrophage in filtration and its prognostic implications in breast cancer: The relationship with VEGF expression and microvessel density. Oncol Rep. 2005; 14:425-31.
31. Sloan EK, Priceman SJ, Cox BF, et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010; 70: 7042-52.
32. Sood AK, Armaiz-Pena GN, Halder J, et al. Adrenergic modulation offocal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest. 2010; 120:1515-23.
33. Sastry KS, Karpova Y, Prokopovich S, et al. Epinephrine protects cancer cells from apoptosis via activation of cAMP-dependent protein kinase and BAD phosphorylation. J Biol Chem. 2007; 282:14094-100.
34. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002; 3:991-8.
35. Andersen BL, Farrar WB, Golden-Kreutz DM, et al. Psychological, behavioral, and immune changes after a psychological intervention: A clinical trial. J Clin Oncol. 2004; 22:3570-80.
36. Thornton LM, Andersen BL, Crespin TR, Carson WE. Individual trajectories in stress covary with immunity during recovery from cancer diagnosis and treatments. Brain Behav Immun. 2007; 21:185-94.
37. Penedo FJ, Dahn JR, Kinsinger D, et al. Anger suppression mediates the relationship between optimism and natural killer cell cytotoxicity in men treated for localized prostate cancer. J Psychosom Res. 2006; 60:423-7.
38. Lutgendorf SK, Sood AK, Anderson B, et al. Social support, psychological distress, and natural killer cell activity in ovarian cancer. J Clin Oncol. 2005; 23: 7105-13.
39. Lutgendorf SK, Lamkin DM, DeGeest K, et al. Depressed and anxious mood and T-cell cytokine expressing populations in ovarian cancer patients. Brain Behav Immun. 2008; 22:890-900.
40. Lutgendorf SK, DeGeest K, Sung CY, et al. Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun. 2009; 23:176-83.
41. Antonova L, Mueller CR. Hydrocortisone downregulates the tumor suppressor gene BRCA1 in mammary cells: A possible molecular link between stress and breast cancer. Genes Chromosomes Cancer. 2008; 47:341-52.
42. Pang D, Kocherginsky M, Krausz T, Kim SY, Conzen SD. Dexamethasone decreases xenograft response to Paclitaxel through inhibition of tumor cell apoptosis. Cancer Biol Ther. 2006; 5:933-40.
43. Flint MS, Kim G, Hood BL, Bateman NW, Stewart NA, Conrads TP. Stress hormones mediate drug resistance to paclitaxel in human breast cancer cells through a CDK-1-dependent pathway. Psychoneuroendocrinology. 2009; 34:1533-41.
44. Zhao XY, Malloy PJ, Krishnan AV, et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat Med. 2000; 6:703-6.
45. Thornton LM, Andersen BL, Carson 3rd WE. Immune, endocrine, and behavioral precursors to breast cancer recurrence: A case-control analysis. Cancer Immunol Immunother. 2008; 57:1471-81.
46. Sephton SE, Sapolsky RM, Kraemer HC, Spiegel D. Diurnal cortisol rhythm as a predictor of breast cancer survival. J Natl Cancer Inst. 2000; 92:994-1000.
47. Sephton SE, Dhabhar FS, Keuroghlian AS, et al: Depression, cortisol, and suppressed cellmediated immunity in metastatic breast cancer. Brain Behav Immun 2009; 23:1148-1155.
48. Weinrib AZ, Sephton SE, Degeest K, et al. Diurnal cortisol dysregulation, functional disability, and depression in women with ovarian cancer. Cancer. 2010; 116:4410-9.
49. Antoni MH, Lutgendorf SK, Cole SW, et al. The Influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer. 2006; 6:240-8.
50. Glaser R, Kiecolt-Glaser JK. Stress-associated immune modulation and its implications for reactivation of latent herpesviruses. In: Glaser R, Jones J, editors. Human herpesvirus infections. New York: Dekker; 1994. p. 245-70.
51. Glaser R, Kiecolt-Glacer J, Stout J, Tarr K, Speicher C, Holliday J. Stress-related impairments in cellular immunity. Psychiatry Res. 1985; 16:233-9.
52. Glaser R, Pearl D, Kiecolt-Glaser J, Malarkey W. Plasma cortisol levels and reactivation of latent Epstein-Barr virus in response to examination stress. Psychoneuroendocrinology. 1994; 19:765-72.
53. Glaser R, Pearson G, Bonneau R, Esterling B, Atkinson C, Kiecolt-Glaser J. Stress and the memory T-cell response to the Epstein-Barr virus in healthy medical students. Health Psychol. 1993; 12:435-42.
54. Zur Hausen H. Papillomaviruses in the causation of human cancers-A brief historical account. Virology. 2009; 384:260-5.
55. Coker AL, Bond S, Madeleine MM, Luchok K, Pirisi L. Psychosocial stress and cervical neoplasia risk. Psychosom Med. 2003; 65:644-51.
56. Pereira DB, Antoni MH, Danielson A, et al. Life stress and cervical squamous intraepithelial lesions in women with human papillomavirus and human immunode ficiency virus. Psychosom Med. 2003; 65: 427-34.
57. Cole SW, Korin YD, Fahey JL, Zack JA. Norepinephrine accelerates HIV replication via protein kinase A-dependent effects on cytokine production. J Immunol. 1998; 161:610-6.
58. Chang H, Dittmer DP, Shin YC, Hong Y, Jung JU. Role of Notch signal transduction in Kaposi's sarcoma-associated herpesvirus gene expression. J Virol. 2005; 79:14371-82.
59. Turgeman H, Aboud M. Evidence that protein kinase A activity is required for the basal and tax-stimulated transcriptional activity of human T-cell leukemia virus type-I long terminal repeat. FEBS Lett. 1998; 428:183-7.
60. Fagundes CP, Bennett BM, Alfano CM, et al. Social support and socioeconomic status interact to predict Epstein-Barr virus latency in women awaiting diagnosis or newly diagnosed with breast cancer. Health Psychol. 2012; 31(1):11-9.
61. Stowe R, Peek M, Perez N, Yetman D, Cutchin M, Goodwin J. Herpesvirus reactivation and socioeconomic position: A community-based study. J Epidemiol Community Health. 2010; 64:666.
62. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW. From Inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008; 9:46-56.
63. Maier SF, Watkins LR. Cytokines for psychologists: implications of bidirectional immune-to-brain communication for understanding behavior, mood, and cognition. Psychol Rev. 1998; 105:83-107.
64. Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biol Psychiatry. 2009; 66: 407-14.
65. Raison CL, Capuron L, Miller AH. Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol. 2006; 27:24-31.
66. Bower JE, Ganz PA, Desmond KA, et al. Fatigue in long-term breast carcinoma survivors: A longitudinal investigation. Cancer. 2006; 106:751-8.
67. Ganz PA, Desmond KA, Leedham B, Rowland JH, Meyerowitz BE, Belin TR. Quality of life in longterm, disease-free survivors of breast cancer: A followup study. J Natl Cancer Inst. 2002; 94:39-49.
68. Cleeland CS, Bennett GJ, Dantzer R, et al. Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine-immunologic model of cancer symptoms. Cancer. 2003; 97: 2919-25.
69. Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR. Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res. 2006; 12:2759-66.
70. Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proInflammatory cytokine activity in breast cancer survivors. Psychosom Med. 2002; 64:604-11.
71. Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J. Evidence report on the occurrence, assessment, and treatment offatigue in cancer patients. J Natl Cancer Inst Monogr. 2004; 32:40-50.
72. Smets E, Garssen B, Schuster-Uitterhoeve A, De Haes J. Fatigue in cancer patients. Br J Cancer. 1993; 68:220.
73. Prue G, Rankin J, Allen J, Gracey J, Cramp F. Cancerrelated fatigue: A critical appraisal. Eur J Cancer. 2006; 42:846-63.
74. Bower JE, Ganz PA, Aziz N, Fahey JL, Cole SW. T-cell homeostasis in breast cancer survivors with persistent fatigue. J Natl Cancer Inst. 2003; 95: 1165-8.
75. Bower JE, Ganz PA, Aziz N, Olmstead R, Irwin MR, Cole S. Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav Immun. 2007; 21: 251-8.
76. Bower JE. Cancer-related fatigue: links with Inflammation in cancer patients and survivors. Brain Behav Immun. 2007; 21:863-71.
77. Bierhaus A, Wolf J, Andrassy M, et al. A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A. 2003; 100: 1920-5.
78. Tracey KJ. Reflex control of immunity. Nat Rev Immunol. 2009; 9:418-28.
79. Fagundes CP, Murray DM, Hwang BS, et al. Sympathetic and parasympathetic activity in cancerrelated fatigue: more evidence for a physiological substrate in cancer survivors. Psychoneuroendocrinology. 2011; 36(8):1137-47.
80. Bower JE, Ganz PA, Aziz N. Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med. 2005; 67:277-80.
81. Raison CL, Miller AH. Depression in cancer: new developments regarding diagnosis and treatment. Biol Psychiatry. 2003; 54:283-94.
82. McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB. Depression in patients with cancer: diagnosis, biology, and treatment. Arch Gen Psychiatry. 1995; 52:89.
83. Spiegel D, Giese-Davis J. Depression and cancer: mechanisms and disease progression. Biol Psychiatry. 2003; 54:269-82.
84. Alesci S, Martinez PE, Kelkar S, et al. Major depression is associated with signi ficant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications. J Clin Endocrinol Metab. 2005; 90:2522-30.
85. Miller GE, Stetler CA, Carney RM, Freedland KE, Banks WA. Clinical depression and Inflammatory risk markers for coronary heart disease. Am J Cardiol. 2002; 90:1279-83.
86. Bouhuys AL, Flentge F, Oldehinkel AJ, van den Berg MD. Potential psychosocial mechanisms linking depression to immune function in elderly subjects. Psychiatry Res. 2004; 127:237-45.
87. Musselman DL, Miller AH, Porter MR, et al. Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings. Am J Psychiatry. 2001; 158:1252-7.
88. Jehn CF, Kuehnhardt D, Bartholomae A, et al. Biomarkers of depression in cancer patients. Cancer. 2006; 107:2723-9.
89. Bonaccorso S, Puzella A, Marino V, et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001; 105:45-55.
90. Wright C, Strike P, Brydon L, Steptoe A. Acute Inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun. 2005; 19: 345-50.
91. Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet. 2006; 367:29-35.
92. Jacobsen PB, Jim HS. Psychosocial interventions for anxiety and depression in adult cancer patients: achievements and challenges. CA Cancer J Clin. 2008; 58:214-30.
93. Antoni MH, Lechner S, Diaz A, et al. Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer. Brain Behav Immun. 2009; 23:580-91.
94. Lutgendorf SK, Mullen-Houser E, Russell D, et al. Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immun. 2010; 24:1231-40.
95. Moyer A, Sohl SJ, Knapp-Oliver SK, Schneider S. Characteristics and methodological quality of 25 years of research investigating psychosocial interventions for cancer patients. Cancer Treat Rev. 2009; 35:475-84.
96. Reiche EMV, Nunes SOV, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol. 2004; 5:617-25.
97. Ciaramella A, Poli P. Assessment of depression among cancer patients: The role of pain, cancer type and treatment. Psychooncology. 2001; 10:156-65.
98. Couzin J. Cancer research. Probing the roots of race and cancer. Science (New York, NY). 2007; 315:592.
99. Zhang-Salomons J, Qian H, Holowaty E, Mackillop W. Associations between socioeconomic status and cancer survival: choice of SES indicator may affect results. Ann Epidemiol. 2006; 16:521-8.